Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

LSAM-PTX Demonstrates Disease Control, Safety in Locally Advanced Pancreatic Cancer

October 11th 2023

Treatment with intratumoral large surface area microparticle paclitaxel led to disease control and was well tolerated in patients with locally advanced pancreatic cancer.

First-Line TPST-1120 Plus Atezolizumab/Bevacizumab Improves Responses in Unresectable or Metastatic HCC

October 11th 2023

The addition of TPST-1120 to the combination of atezolizumab and bevacizumab led to improved responses vs atezolizumab plus bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

Dr Stein on Key Considerations When Selecting an Immunotherapy Approach in HCC

October 10th 2023

Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: Looking to the Future

October 10th 2023

In this final episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, reiterate that the role of endoscopic therapies in pancreatic cancer continues to evolve.

Biomarker Testing in Gastrointestinal and Lung Cancers

October 6th 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

Molecular Testing in Breast Cancer

October 6th 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

First-Line Motixafortide Plus Cemiplimab/Chemotherapy Induces Responses in mPDAC

October 5th 2023

First-line treatment with the combination of motixafortide, cemiplimab-rwlc, gemcitabine, and nab-paclitaxel elicited responses in patients with metastatic pancreatic adenocarcinoma, according to initial data from the pilot portion of a phase 2 trial.

Evorpacept Plus Trastuzumab/Ramucirumab/Paclitaxel Improves ORR in Pretreated, Advanced HER2+ Gastric/GEJ Cancer

October 3rd 2023

Second- or third-line treatment with the CD47 blocker evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel improved responses vs trastuzumab/ramucirumab/paclitaxel alone in patients with HER2-positive, advanced gastric and gastroesophageal junction cancer.

FDA Grants Fast Track Designation to BI 764532 for ES-SCLC and Extrapulmonary NEC

October 3rd 2023

The FDA has granted a fast track designation to BI 764532 for the treatment of patients with extensive-stage small cell lung cancer that has progressed following at least 2 prior lines of treatment, and for patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma that has progressed following at least 1 prior line of treatment.

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: Pancreatic Cancer Ablation and Immune Modulation

October 3rd 2023

In this sixth episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, briefly discuss pancreatic cancer ablation and immune modulation.

FDA Grants Orphan Drug Designation to BDC-1001 in Gastric Cancers

October 2nd 2023

The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.

Mechanisms of Action of Antibody-Drug Conjugates

September 29th 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

Overview of Antibody-Drug Conjugates (ADCs)

September 29th 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

Zolbetuximab Could Alter Frontline Treatment Paradigm for CLDN18.2+ Gastric/GEJ Cancer

September 28th 2023

Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: Additional Studies Are Needed

September 26th 2023

In this fifth episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, underscore the need for additional research evaluating the role of radiofrequency ablation and other approaches in pancreatic cancer, and avenues that are ripe for further exploration.

First-Line Lutetium Lu 177 Dotatate Plus Octreotide Improves PFS in Advanced Gastroenteropancreatic NETs

September 25th 2023

First-line treatment with lutetium Lu 177 dotatate plus long-acting octreotide led to a statistically significant and clinically meaningful improvement in progression-free survival compared with high-dose long-acting octreotide alone in newly diagnosed patients with somatostatin receptor–positive, grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors.

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20th 2023

Early lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metastases.

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

September 20th 2023

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

FDA Approval Sought for Frontline Tislelizumab in Locally Advanced or Metastatic ESCC

September 19th 2023

The FDA has accepted for review a biologics license application seeking the approval of tislelizumab for use in the frontline treatment of patients with unresectable, recurrent, locally advanced or metastatic esophageal squamous cell carcinoma.

Tislelizumab Approved in Europe for Advanced ESCC After Platinum-Based Chemotherapy

September 19th 2023

The European Commission has approved tislelizumab monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.